News

Dogs with Cancer Could Leave a Lasting Legacy

Publications

Small molecule innate immune modulators in cancer therapy
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Barnali Deb, Aditya Kulkarni

PMID: 39318624 PMCID: PMC11419979 DOI:10.3389/fimmu.2024.1395655

AVA-ADR-001 Suppresses Tumor Growth and Induces Anti-tumor Immunity by Selectively Inhibiting ADAR1 p150
Aditya Kulkarni, Avijit Goswami, Barnali Deb, Ankita Mohanty, Sandeep Goyal, Kawaljit Singh, Rahul Yadav, Princy Khurana, Narenkumar Muralidharan, Jan Rehwinkel

Molecules 2022,27(19), 6721; DOI: 10.3390/molecules27196721

Conference Abstracts

First-in-class Zα-domain-targeted ADAR1 p150 inhibitor demonstrates potent antitumor efficacy in high IFN syngeneic melanoma
Aditya Kulkarni; Avijit Goswami; Sandeep Goyal; Princy Khurana; Kawaljit Singh; Barnali Deb

Cancer Res (2026) 86 (7_Supplement): 1559.

Combination of AVA-NP-695 and DDRi demonstrates strong synergy resulting in potent anti-tumor activity in rare pediatric cancers.
Aditya Kulkarni; Borja Ruiz-Fernandez de Cordoba; Avijit Goswami; Sandeep Goyal; Kawaljit Singh; Princy Khurana; Alejandro Sweet-Cordero

Cancer Res (2026) 86 (7_Supplement): 7877.

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics